Trial Profile
Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study
Status:
Not yet recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 09 Apr 2022
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Lopinavir/ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms BARI-COVID
- 19 Apr 2020 Planned number of patients changed from 60 to 200.
- 19 Apr 2020 Planned End Date changed from 30 Apr 2020 to 30 Jul 2020.
- 19 Apr 2020 Planned primary completion date changed from 30 Apr 2020 to 30 Jun 2020.